Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology (SOT) 2026 Annual Meeting and ToxExpo in San Diego. The presentation highlights findings on tissue concentration-driven effects and organ-specific outcomes, moving beyond traditional plasma pharmacokinetics to understand toxicity profiles. This research underscores the importance of tissue-level drug distribution in determining toxicity and supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations.
The SOT meeting is a premier event for toxicology research, and Sapu Nano's presentation aims to provide insights into how drug accumulation in specific tissues influences adverse effects. By focusing on everolimus, a drug used in oncology and transplant medicine, the study could inform safer dosing regimens and novel formulations that enhance therapeutic index while reducing toxicity. The full press release is available at https://ibn.fm/kZzE3.
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. Oncotelic, through its subsidiaries, is leveraging its expertise in oncology drug development to improve treatment outcomes for cancer patients, with a special emphasis on rare pediatric cancers. The company has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG) through OT-101, melanoma through CA4P, and Acute Myeloid Leukemia (AML) through OXi 4503.
The presentation at SOT 2026 aligns with Oncotelic's strategy to advance its pipeline by optimizing drug delivery. The company's acquisition of PointR Data Inc. in November 2019 aims to build an AI-driven biotechnology company, and the acquisition of AL-101 in 2021 for intranasal delivery of apomorphine expands its focus to neurological and sexual health disorders. For more information on AL-101, refer to Oncotelic's 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025.
This research is significant because it addresses a critical gap in toxicology: understanding how drug distribution at the tissue level, rather than just in plasma, affects safety and efficacy. By presenting these data, Sapu Nano and Oncotelic are contributing to the development of more targeted and safer therapies, potentially benefiting patients in oncology and beyond.
